Status:
COMPLETED
An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung Cancer
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Nonsquamous Nonsmall Cell Neoplasm of Lung
Eligibility:
All Genders
18+ years
Brief Summary
This observational study will evaluate the safety and efficacy of Tarceva (erlotinib) in routine clinical practice as second-line treatment in patients with recurrent or metastatic non-small dell lung...
Eligibility Criteria
Inclusion
- Adult patients ≥ 18 years of age.
- Written informed consent.
- Recurrent or metastatic, Stage III or IV non-small cell lung cancer (NSCLC).
- Measurable disease (Response Evaluation Criteria In Solid Tumors).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Prior course of standard systemic chemotherapy.
Exclusion
- \- Contra-indications to treatment with Tarceva.
Key Trial Info
Start Date :
April 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
347 Patients enrolled
Trial Details
Trial ID
NCT01161173
Start Date
April 1 2008
End Date
August 1 2012
Last Update
March 28 2016
Active Locations (36)
Enter a location and click search to find clinical trials sorted by distance.
1
Aalst, Belgium, 9300
2
Antwerp, Belgium, 2020
3
Arlon, Belgium, 6700
4
Bonheiden, Belgium, 2820